Susquehanna International Group
PVLA

Susquehanna International Group’s Palvella Therapeutics PVLA Stock Holding History

Susquehanna International Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.34M Buy
+18,808
New +$1.96M ﹤0.01% 5798
2025
Q4 		– Sell
-8,008
Closed -$683K – 13957
2025
Q3 		$502K Sell
8,008
-9,376
-54% -$418K ﹤0.01% 8938
2025
Q2 		$392K Sell
17,384
-97,004
-85% -$2.28M ﹤0.01% 9741
2025
Q1 		$3.2M Buy
+114,388
New +$2.2M ﹤0.01% 4528
2024
Q1 		– Sell
-1,287
Closed -$18.7K – 13580
2023
Q4 		$18.7K Buy
+1,287
New +$23.6K ﹤0.01% 11986
2023
Q2 		– Sell
-199
Closed -$15.5K – 13340
2023
Q1 		$15.5K Buy
+199
New +$23K ﹤0.01% 12110
2022
Q3 		– Sell
-421
Closed -$54.3K – 14290
2022
Q2 		$63K Sell
421
-4,211
-91% -$768K ﹤0.01% 11837
2022
Q1 		$1.12M Sell
4,632
-334
-7% -$87.8K ﹤0.01% 6827
2021
Q4 		$1.5M Sell
4,966
-845
-15% -$271K ﹤0.01% 6207
2021
Q3 		$2.4M Buy
5,811
+3,544
+156% +$1.23M ﹤0.01% 5447
2021
Q2 		$694K Buy
+2,267
New +$497K ﹤0.01% 8764
2021
Q1 		– Sell
-297
Closed -$59K – 12948
2020
Q4 		$59K Buy
297
+153
+106% +$31.8K ﹤0.01% 10708
2020
Q3 		$24K Buy
144
+16
+13% +$3.64K ﹤0.01% 10363
2020
Q2 		$32K Sell
128
-181
-59% -$42.3K ﹤0.01% 9857
2020
Q1 		$56K Buy
309
+52
+20% +$13.1K ﹤0.01% 9633
2019
Q4 		$74K Sell
257
-486
-65% -$135K ﹤0.01% 9240
2019
Q3 		$203K Buy
743
+186
+33% +$72K ﹤0.01% 9072
2019
Q2 		$209K Buy
+557
New +$166K ﹤0.01% 9055
2019
Q1 		– Sell
-718
Closed -$153K – 10004
2018
Q4 		$153K Sell
718
-211
-23% -$65.5K ﹤0.01% 7967
2018
Q3 		$416K Sell
929
-280
-23% -$122K ﹤0.01% 6867
2018
Q2 		$490K Sell
1,209
-238
-16% -$113K ﹤0.01% 6827
2018
Q1 		$790K Buy
1,447
+1,018
+237% +$630K ﹤0.01% 5721
2017
Q4 		$259K Buy
+429
New +$199K ﹤0.01% 7831
2015
Q3 		– Sell
-1,617
Closed -$356K – 10306
2015
Q2 		$356K Buy
+1,617
New +$356K ﹤0.01% 8252

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Susquehanna International Group's PVLA Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 18,808 shares worth $2.34M. The stake represents ﹤0.01% of the portfolio and ranks #5798 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in PVLA as recently as Q3 2025.

Susquehanna International Group first reported a position in PVLA in Q2 2015 and has held it in 24 quarters since. The position peaked at $3.2M in Q1 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Susquehanna International Group held 18,808 shares of Palvella Therapeutics worth $2.34M as of Q1 2026.
  • Palvella Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Palvella Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5798 holding.
  • Susquehanna International Group first reported a position in Palvella Therapeutics in Q2 2015 and has held it in 24 quarters since.
  • Susquehanna International Group's Palvella Therapeutics position peaked at $3.2M in Q1 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.